Hypoparathyroidism - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Hypoparathyroidism - Pipeline Review, H1 2016', provides an overview of the Hypoparathyroidism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypoparathyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypoparathyroidism and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Hypoparathyroidism - The report reviews pipeline therapeutics for Hypoparathyroidism by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Hypoparathyroidism therapeutics and enlists all their major and minor projects - The report assesses Hypoparathyroidism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Hypoparathyroidism Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Hypoparathyroidism - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Hypoparathyroidism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Hypoparathyroidism Overview 6 Therapeutics Development 7 Pipeline Products for Hypoparathyroidism - Overview 7 Hypoparathyroidism - Therapeutics under Development by Companies 8 Hypoparathyroidism - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Hypoparathyroidism - Products under Development by Companies 12 Hypoparathyroidism - Companies Involved in Therapeutics Development 13 Chugai Pharmaceutical Co., Ltd. 13 Rare Disease Therapeutics, Inc. 14 Shire Plc 15 Hypoparathyroidism - Therapeutics Assessment 16 Assessment by Monotherapy Products 16 Assessment by Target 17 Assessment by Mechanism of Action 19 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Drug Profiles 25 Eu-232 - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 parathyroid hormone - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 PCO-371 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 teriparatide - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 teriparatide - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Hypoparathyroidism - Recent Pipeline Updates 32 Hypoparathyroidism - Dormant Projects 35 Hypoparathyroidism - Product Development Milestones 36 Featured News & Press Releases 36 Jan 23, 2015: FDA approves Natpara to control low blood calcium levels in patients with hypoparathyroidism 36 Dec 02, 2014: European Medicines Agency Validates Marketing Authorization Application for Natpar (parathyroid hormone (rDNA)) in Hypoparathyroidism 37 Oct 23, 2014: PDUFA Action Date For Natpara BLA Extended Three Months To January 24, 2015 37 Sep 12, 2014: FDA Advisory Committee Recommends Approval of Natpara for Long-Term Treatment of Hypoparathyroidism 38 Sep 12, 2014: FDA Advisory Committee to Review Natpara Biologics License Application 38 Sep 10, 2014: FDA Posts Briefing Materials for Advisory Committee Meeting Reviewing Natpara for Hypoparathyroidism 38 Jul 24, 2014: PARADOX Findings Published in Endocrine Practice Describe High Burden of Illness in Patients with Hypoparathyroidism 39 Jun 10, 2014: NPS Pharma Reports Change in Tentative Date of FDA Advisory Committee Review of Natpara BLA to September 12 - PDUFA Date of October 24 Remains Unchanged 40 Jan 07, 2014: NPS Pharmaceuticals Announces FDA Acceptance of Biologics License Application for Natpara for the Treatment of Hypoparathyroidism 40 Jan 03, 2014: NPS Pharmaceuticals Receives Orphan Drug Designation for Natpara in Europe 41 Appendix 42 Methodology 42 Coverage 42 Secondary Research 42 Primary Research 42 Expert Panel Validation 42 Contact Us 42 Disclaimer 43
List of Tables
Number of Products under Development for Hypoparathyroidism, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Hypoparathyroidism - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2016 13 Hypoparathyroidism - Pipeline by Rare Disease Therapeutics, Inc., H1 2016 14 Hypoparathyroidism - Pipeline by Shire Plc, H1 2016 15 Assessment by Monotherapy Products, H1 2016 16 Number of Products by Stage and Target, H1 2016 18 Number of Products by Stage and Mechanism of Action, H1 2016 20 Number of Products by Stage and Route of Administration, H1 2016 22 Number of Products by Stage and Molecule Type, H1 2016 24 Hypoparathyroidism Therapeutics - Recent Pipeline Updates, H1 2016 32 Hypoparathyroidism - Dormant Projects, H1 2016 35
List of Figures
Number of Products under Development for Hypoparathyroidism, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Clinical Stage Development, H1 2016 10 Assessment by Monotherapy Products, H1 2016 16 Number of Products by Targets, H1 2016 17 Number of Products by Stage and Targets, H1 2016 17 Number of Products by Mechanism of Actions, H1 2016 19 Number of Products by Stage and Mechanism of Actions, H1 2016 19 Number of Products by Routes of Administration, H1 2016 21 Number of Products by Stage and Routes of Administration, H1 2016 21 Number of Products by Molecule Types, H1 2016 23 Number of Products by Stage and Top 10 Molecule Types, H1 2016 23
Global contact lenses market size is estimated to reach USD 12.5 billion by 2020, according to a new industry report by Radiant Insights, Inc. Growing number of ophthalmic disorder observed in global population especially children is likely to driveRead More...
Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is antRead More...
Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the glRead More...
Global adhesives & sealants market size is expected to reach USD 43.19 billion by 2020, as per a new research report by Radiant Insights, Inc. Strong demand from packaging, construction and automotive industries is expected drive adhesives and sealanRead More...
Global fluorotelomers market size is anticipated to be valued at USD 539.3 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing application scope in fire fighting systems owing to growing safety concerns is likely to driRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.